MedTrace Logo

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-03-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.

Conditions

Interventions

BIOLOGICAL

abatacept

Abatacept administered SC weekly at 125 mg dose

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Arthritis & Rheumatic Disease Specialties Research

    lead OTHER

Principal Investigators

  • Norman B Gaylis, MD · Arthritis & Rheumatic Disease Specialties Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-01-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01351480 on ClinicalTrials.gov